Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic

This image opens in the lightbox

News provided by

InsightAce Analytic Pvt. Ltd.

03 Feb, 2022, 13:15 GMT

Share this article

Share toX

Share this article

Share toX

JERSEY CITY, N.J., Feb. 3, 2022 /PRNewswire/ -- The newly published report titled "Global Gene Therapy for Blood Disorders Market– By Trends, Industry Competition Analysis, Pipeline Analysis/Clinical Trial, Revenue (US$ Billions) and Forecast Till 2030." features in-depth analysis and an extensive market study, exploring its significant upcoming years industry factors.

According to the latest gene therapy industry market research report, the global gene therapy for blood disorders market size was valued at US$ 1.13 Billion in 2021, and it is expected to reach US$ 5.79 Billion in 2030, recording a promising CAGR of 21.6 % during the forecast period of 2022 to 2030.

Get the Sample Report: https://www.insightaceanalytic.com/request-sample/1156

Genetic therapy is used to alter human genes for the treatment of diseases. It has excellent potential for treating rare blood diseases such as sickle cell disease and hemophilia. Various biopharma companies are switching to gene-editing technique, CRISPR-Cas9, as a tool to fight rare diseases. CRISPR Therapeutics is conducting a phase I / II trial of CRISPR / Cas9-based genetic therapy, CTX001, to treat sickle cell disease in partnership with Vertex Pharmaceuticals. The increasing prevalence of genetic and blood disorders, high demand for personalized medicine, increased healthcare expenditure, increased R&D activities to develop promising genetic therapies for hematology are expected to boost the market growth in the upcoming years. According to a study published in the PLOS Medicine Journal, cases of sickle cell anemia are projected to increase by about 30% worldwide by 2050. Therefore, the increase in rare hematology disorders is a major driving factor in this market.

However, the high cost of gene therapy treatment and the potential side effects of the therapies are expected to hinder the penetration of gene therapy treatment during the forecast period. 

Prview for Detailed ToC: https://www.insightaceanalytic.com/report/global-gene-therapy-for-blood-disorders-market/1156 

 The prominent players in the gene therapy for blood disorders industry include:

BioMarin Pharmaceutical Inc. (U.S.), Medgenics (U.S.), Spark Therapeutics (U.S.), bluebird bio, Inc. (U.S.), Shire (U.S.), CRISPR Therapeutics (U.S.), Freeline Therapeutics (U.K.), OrphageniX (U.S.), Errant Gene Therapeutics (U.S.), Sangamo Therapeutics (U.S.), Sigilon Therapeutics, Inc. (U.S.), uniQure (Netherlands), Angiocrine Bioscience (U.S.), and Sanofi Genzyme (U.S.), and other prominent players.

Gene Therapy for Blood Disorders Market Regional Analysis:

North America is predicted to account for the largest share of the gene therapy for blood disorders market during the forecast years, followed by Europe, owing to the rising prevalence of various blood disorders, well-developed healthcare systems, and increasing R&D investments to develop effective gene therapies to treat rare diseases. According to the Hemophilia Federation of America, Hemophilia affects 1 in 5,000 male births, and around 400 babies are born with hemophilia in the U.S annually. Worldwide 400,000 individuals are living with hemophilia, and approximately 20,000 people are living with it in the United States alone.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1156

The Global Gene Therapy for Blood Disorders Market Segments

The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Indication

  • Sickle Cell Anemia
  • β-thalassemia
  • Hemophilia B
  • Hemophilia A
  • Other Indication

The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Mechanism of Action

  • Gene Therapy
  • Gene Editing

The Global Gene Therapy for Blood Disorders Market Estimates (Value US$ Million) & Forecasts and Trend Analyses, 2021 to 2030 based on Region

  • Europe
  • North America
  • Latin America
  • Asia Pacific
  • Middle East & Africa

North America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030

  • U.S.
  • Canada

Europe Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030

  • Germany
  • Spain
  • France
  • Russia
  • Italy
  • Rest of Europe

Asia Pacific Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030

  • India
  • Japan
  • China
  • Australia & New Zealand
  • South Korea

Latin America Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

The Middle East & Africa Gene Therapy for Blood Disorders Market Estimates Revenue (US$ Million) by Country, 2021 to 2030

  • South Africa
  • GCC Countries
  • Rest of the Middle East & Africa

For Customised Information @ https://www.insightaceanalytic.com/customisation/1156

Other Related Reports Published by InsightAce Analytic:

Global Cell and Gene Therapy Drug Delivery Devices Market

Global Gene Therapies For Rare Diseases Market

Global Gene Therapy For Retinal Diseases Market

Global mRNA Synthesis and Manufacturing Services Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Email: info@insightaceanalytic.com 
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg 

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.